Monitor August 2026 ELPIS II readout as the primary catalyst; cash runway into Q4 2026 provides some buffer but additional financing will be needed. The private placement was dilutive (shares outstanding increased from 21.4M to 29.3M), but necessary for operations.
LGVN drugs
LGVN drug pipeline →How the stock moved after the report
NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · May 14 $0.7030entry
- T+1 · 6mo ago −4.55%α −3.32% · $0.6710
- T+5 · 6mo ago +2.56%α +3.28% · $0.7210
- T+20 · 5mo ago +11.38%α +12.24% · $0.7830
- T+60 · 3mo ago +4.74%α +1.15% · $0.7363
Price Chart
How similar events traded
Executive Summary
Longeveron reported Q1 2026 results in line with consensus: EPS -$0.19 matched Street estimates and revenue of $398K was essentially flat YoY. The key positive was a strengthened cash position of $15.8M following a $15M private placement, extending runway into Q4 2026. The primary catalyst remains top-line data from the ELPIS II Phase 2b HLHS trial expected in August 2026.
Key Financial Metrics
Key Facts
- Q1 2026 EPS -$0.19 (in line with consensus of -$0.19)
- Q1 2026 revenue $398K vs $381K in Q1 2025 (flat)
- Cash and equivalents $15.8M as of March 31, 2026 vs $4.7M at year-end 2025
- Closed $15M private placement (up to $30M) led by Coastlands Capital
- Cash runway extended into Q4 2026
- ELPIS II Phase 2b HLHS top-line results anticipated in August 2026
Financial Impact
No material financial impact from earnings; cash position improved by ~$11M from prior quarter
Risk Factors
- Dilution from PIPE and potential future offerings
- Single point of failure on ELPIS II trial results
- Need for additional capital before Q4 2026
- Pre-revenue stage with ongoing operating losses
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001213900-26-055806 |
| Document: ea0290436-8k_longeveron.htm | 0001213900-26-055806 |
| Document: 0001213900-26-055806-index-headers.html | 0001213900-26-055806 |
| Document: 0001213900-26-055806-index.html | 0001213900-26-055806 |
| Document: 0001213900-26-055806.txt | 0001213900-26-055806 |
| 8-K Data (Synthetic) | 0001213900-26-055806 |
Track record
22 reports on LGVN
4 of 5 bullish or bearish reports moved the stock their way by T+60. Best: +44.65% at T+20 after the Sep 16, 2026 report. 7 of 9 went positive at some point.
Filters
- Nov 16, 2026today SC 13G/A Bearish 4/10 Entry $2.53 Now $2.14 +15.42% settles Feb 12
- Nov 13, 20263d ago SC 13G Neutral 4/10 Entry $2.49 Now $2.14 −14.06% settles Feb 11
- Nov 12, 20264d ago 8-K Bearish 7/10 No price data
- Nov 12, 20264d ago Press Release Bearish 6/10 Entry $2.49 Now $2.14 +14.06% settles Feb 11
- Nov 5, 202611d ago SC 13G/A Bearish 5/10 Entry $1.81 Now $2.14 −18.23% settles Feb 4
- Nov 5, 202611d ago 8-K Neutral 2/10 Entry $1.81 Now $2.14 +18.23% settles Feb 4
- Oct 26, 202621d ago 8-K Neutral 5/10 Entry $1.73 Now $2.14 +23.70% settles Jan 25
- Oct 26, 202621d ago Press Release Mixed 6/10 Entry $1.61 Now $2.14 +33.33% settles Jan 22
- Oct 14, 20264w ago 8-K Neutral 3/10 Entry $1.50 Now $2.14 +42.67% settles Jan 12
- Sep 16, 20268w ago Press Release Bearish 7/10 Entry $2.71 Now $2.14 +21.03% settles Dec 11
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers